Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed duration MDT in paucibacillary leprosy.

R Mathai1, S George, M Jacob

  • 1Department of Dermatology, Christian Medical College & Hospital, Vellore, South India.

International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association
|June 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Underestimating the impact of water fluoridation.

British dental journal·2024
Same author

On-site treatment of avalanche victims: Scoping review and 2023 recommendations of the international commission for mountain emergency medicine (ICAR MedCom).

Resuscitation·2023
Same author

Veterinary Medical Society, University of Pennsylvania.

The Journal of comparative medicine and veterinary archives·2022
Same author

Veterinary Medical Society of the University of Pennsylvania.

The Journal of comparative medicine and veterinary archives·2022
Same author

Veterinary Medical Society of the University of Pennsylvania.

The Journal of comparative medicine and veterinary archives·2022
Same author

Veterinary Medical Society, University of Pennsylvania.

The Journal of comparative medicine and veterinary archives·2022

Multidrug therapy (MDT) for paucibacillary leprosy shows limited advantage over dapsone monotherapy. Many patients on MDT still exhibit active disease signs post-treatment, indicating potential limitations in current WHO recommendations.

Area of Science:

  • Dermatology
  • Infectious Diseases
  • Clinical Pathology

Background:

  • The World Health Organization (WHO) established fixed-duration multidrug therapy (MDT) for paucibacillary leprosy, widely adopted in India.
  • A comparative clinico-pathological study was conducted to evaluate MDT's efficacy against conventional dapsone (DDS) monotherapy.

Purpose of the Study:

  • To assess the clinical and histological efficacy of WHO-recommended MDT for paucibacillary leprosy.
  • To compare the treatment outcomes of MDT with dapsone monotherapy.

Main Methods:

  • A clinico-pathological study initiated in 1984 compared MDT with dapsone monotherapy.
  • Patient responses were assessed at 6 months (treatment cessation) and 2.5 years (surveillance release).
  • Histological and clinical improvements were evaluated for both treatment groups.

Related Experiment Videos

Main Results:

  • At 2.5 years, 20% of patients on MDT showed less than 60% improvement, indicating persistent active disease.
  • In contrast, only 8.8% of patients on dapsone monotherapy had less than 60% improvement at 2.5 years.
  • At 6 months, 33% of MDT patients and 37% of dapsone patients had less than 60% improvement.

Conclusions:

  • WHO-recommended MDT for paucibacillary leprosy may not offer significant advantages over dapsone monotherapy.
  • A notable percentage of patients on MDT continue to show signs of active leprosy upon completion of surveillance.
  • Further evaluation of leprosy treatment regimens may be warranted to improve long-term outcomes.